



Trend Macrolytics, LLC Donald Luskin, Chief Investment Officer Thomas Demas, Managing Director Michael Warren, Energy Strategist


Data Insights: Covid-2019 Monitor

Monday, January 2, 2023

The global scorecard









For more information contact us: Donald Luskin: 214 550 2121 <u>don@trendmacro.com</u> Thomas Demas: 704 552 3625 <u>tdemas@trendmacro.com</u>

Copyright 2023 Trend Macrolytics LLC. All rights reserved. This document is not to be forwarded to individuals or organizations not authorized by Trend Macrolytics LLC to receive it. For information purposes only; not to be deemed to be recommendations for buying or selling specific securities or to constitute personalized investment advice. Derived from sources deemed to be reliable, but no warranty is made as to accuracy.



Source: Johns Hopkins, Dept. of Health and Human Services, CDC, TrendMacro calculations


China provincial coronavirus <u>case</u> accelerometer... tracking the "zero Covid" curves *Cumulative reported cases this year, log scale: flat line indicates "zero Covid"*




Source: Johns Hopkins, TrendMacro calculations


| Rolling out the vaccines in the US and the world <u>Updates weekly on Friday</u> | | | | | | | | | | | | |
|--|------------------|---------------------------|-------------|------------------|--------------------|--------------------|----------------|----------------|------------------|-----------------|--------------|-------|
| Administered Cumula | | | | | | | Today | | Immunity | Full | Partial | |
| Doses | | 680,393,511 | | | | +0.244 million | | US | 69.0% | 80.8% | | |
| | | | | | | Of which boosters: | | +0.214 million | | UK | 75.2% | 79.7% |
| | | One dose | | % Pop Im 83% 2 | | nune | % рор | New imm | une today | France | 78.4% | 80.6% |
| Total popu | Total population | | 276,758,611 | | 23 | 235,944,128 | | +0.021 million | | Spain | 85.5% | 86.9% |
| - | Age 12 to 17 | | 18,413,123 | | 1 | 15,763,488 | | +0.001 million | | Germany | 76.2% | 77.8% |
| Age 18 to 64 | | 184,058,504 | | 90% | 15 | 156,476,533 | | +0.013 million | | Italy | 81.3% | 86.2% |
| Age 65 and over | | 60,960,848 | | 100% | 5 | 53,388,685 | | +0.004 million | | Australia | 82.7% | 84.9% |
| Other 3% Moderna 38% Pfizer 59% AK 72.8% | | | | | | | | | | Israel | 65.2% | 71.1% |
| | | | | | _ | | | | | Canada | 82.5% | 90.0% |
| | | State | | Best | | | | | | | 83.2% | 84.3% |
| | | | | 2000 | | | | | | Africa India | 27.5% | 33.5% |
| | | At least partial immunity | | Middle | | | | | | | 67.1% | 72.5% |
| | | as % population | | Wildle | | | | | | Brazil China | 81.2% | 87.6% |
| | | Full immunity | | Worst | | | | | | 89.4% | 91.7% | |
| | | as % population | | | | | | | Global data diff | | rces, timing | |
| | | "Immunity" = two doses | | | | WI | | As of Dec 30 | As of Dec 30 | | ME | |
| 64.9% | | | | | | 74.9% | | | | 95.0% | | |
| | | | | | | 68.0% | | 1 | | | 83.0% | |
| | WA | ID | MT | ND | MN | IL | MI | | NY | VT | NH | |
| | 84.9% | 63.7% | 68.0% | 69.1% | 78.5% | 78.9% | 69.3% | | 94.1% | 95.0% | 87.5% | |
| | 75.7% | 56.3% | 59.0% | 58.4% | 71.9% | 71.0% | 62.2% | | 80.5% | 85.3% | 71.5% | l |
| | OR | NV | WY | SD | IA | IN | OH | PA | NJ | MA | | |
| | 81.2% | 77.3% | 60.7% | 83.4% | 70.4% | 64.2% | 65.5% | 90.1% | 94.3% | 95.0% | | |
| | 72.1% CA | 63.5% UT | 52.9% | 66.0% NE | 64.2% M0 | 57.6% KY | 60.3% WV | 72.9% VA | 78.8% | 83.8% CT | RI | 1 |
| | | | CO | | | | | | MD | | | |
| | 84.3% | 75.0% | 83.3% | 73.1% | 69.1% | 68.6% | 67.3% | 90.6% | 91.3% | 95.0% | 95.0% | |
| _ | 74.4% | 66.5% AZ | 73.2% NM | 66.0% KS | <u>58.8%</u> AR | <u>59.4%</u> TN | 59.6% NC | 76.3% SC | 79.4% DC | 82.8% DE | 87.4% | 1 |
| | | 77.1% | 93.8% | 75.9% | 69.6% | 64.3% | 91.6% | 70.7% | 95.0% | 87.7% | | |
| | | 65.8% | | | 56.7% | 64.3% 56.2% | | | 95.0% 85.3% | | | |
| | | 00.0% | 74.9% | 65.0% OK | LA | 00.2% MS | 66.8% AL | 59.7% GA | 80.3% | 72.9% | | |
| | | | | 74.3% | 62.7% | | | 68.1% | | | | |
| HI | | | | | | 61.5% 52.6% | 64.8% 53.0% | | | | | |
| 91.1% | | | | 60.2% TX | 54.9% | 53.6% | 05.0% | 57.1% | FL | 1 1 | PR | 1 |
| 81.3% | | | | 76.0% | | | | | FL 82.1% | | 95.0% | |
| 01.070 | | | | | | | | | | | | |
| | | | | 63.0% | | | | | 69.2% | | 86.7% | J |


The demographics of US vaccination





US deep-dive
























Source: Johns Hopkins, Covid Act Now, TrendMacro calculations




Source: Distributions <u>CDC</u>, Comorbidities <u>CDC</u>, TrendMacro calculations

Recommended reading


Xi Jinping has abandoned zero-Covid. What happens now?

Ellen loanes *Vox* January 1, 2023 <u>As COVID turns 3, experts worry where the next</u> <u>pandemic will come from – and if we'll be ready</u> Karen Weintraub *USA Today* January 1, 2023




Source: Our beloved clients, **Power Line blog "The Week in Pictures"** and **CTUP**


The global coronavirus <u>case</u> accelerometer... tracking the world's infection curves Share of infected population from first day with 100 confirmed cases, log scale



Source: Johns Hopkins, TrendMacro calculations




The global coronavirus <u>mortality</u> accelerometer ... tracking the world's fatality curves *Share of population deceased from day of first fatality, log scale*



Source: Johns Hopkins, TrendMacro calculations




Source: Johns Hopkins, TrendMacro calculations




Source: Covid Act Now, TrendMacro calculations

From Ground Zero to the Rio Grande


Cases: 7-day average and daily Deaths: Daily




Source: Johns Hopkins, TrendMacro calculations









Cases: 7-day average and daily Deaths: Daily






Source: Johns Hopkins, TrendMacro calculations







Source: Johns Hopkins, TrendMacro calculations










Impact in the BRICs ex-China Cases: 7-day









TrendMacro Data Insights: Covid-2019 Monitor